Conversely, significantly higher levels of tumor-promoting, pro-angiogenic factors Tie2 and VEGF were detected in the pre-treatment serum of patients who had adverse tumor features following neo-adjuvant treatment which are associated with poorer responses and prognoses [29]. The gene discussed is TEK; the disease is neoplasm.